Foghorn outlines 2024 pipeline milestones; AML combo data expected H2, six INDs over four years

Foghorn Therapeutics Inc.

FHD-286 Phase 1 combination study in AML continues; first data expected H2 2024.
Preclinical combo data with TKIs in EGFR/KRAS resistance expected Q2 2024.
Selective EP300 and CBP degraders show efficacy without thrombocytopenia; CBP IND enabling studies targeted before end of 2024.
At least six new INDs planned over next four years across >20 tumor types.
Cash $259.9M as of Sep 30, 2023; runway into H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.